Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), has appointed Matthew Delaney to vice president of business development and marketing. Delaney will serve on the senior leadership team and report to Dr. Jesse McCool, CEO of Cytovance Biologics.
 
“We are delighted to welcome Matt onto the Senior Leadership Team in Oklahoma City. His two decades of BD and marketing experience combined with a deep knowledge of the CDMO markets will help accelerate Cytovance’s expansion into the rapidly growing biologics and gene therapy sectors,” said McCool. “Matt shows up with integrity, high energy and a clear commitment to understanding and exceeding the needs of our customers. I’m very pleased to have him on my team.”
 
In this role, Delaney will be responsible for the leadership of the Cytovance Biologics sales and marketing teams, developing new business opportunities and creating customized solutions to meet unique customer requirements. Delaney will lead the continued acceleration of Cytovance’s revenue growth through the expansion of the company’s R&D and CGMP mammalian and microbial pipelines along with its recent entry into the gene therapy space.
 
Prior to joining Cytovance in August 2019, Delaney earned 20 years of experience where he served as president of Datatrak International – a Software as a Service (SaaS Model) solution provider, the vice president of Pharm-Olam International – a CRO, and roles with Nitto Avecia – a CDMO R&D and CGMP biotech company.